Anzeige
Mehr »
Freitag, 10.10.2025 - Börsentäglich über 12.000 News
3 kritische Rohstoffe. 1 riesiges Becken. $2,26 Mrd. US-Finanzierung: Diese Aktie könnte die Nächste sein!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14QXP | ISIN: FR0012127173 | Ticker-Symbol: 6OP
Tradegate
10.10.25 | 20:12
6,585 Euro
-6,06 % -0,425
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
OSE IMMUNOTHERAPEUTICS SA Chart 1 Jahr
5-Tage-Chart
OSE IMMUNOTHERAPEUTICS SA 5-Tage-Chart
RealtimeGeldBriefZeit
6,5406,70522:26
6,5456,60522:00

Aktuelle News zur OSE IMMUNOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
03.10.OSE ImmunoTherapeutics replaces CEO Nicolas Poirier, appoints Marc Le Bozec as interim CEO3
03.10.OSE Immunotherapeutics Names Marc Le Bozec Interim CEO, Effective Immediately1
03.10.OSE Immunotherapeutics appoints Marc Le Bozec as interim CEO10
03.10.OSE Immunotherapeutics beruft Marc Le Bozec zum Interims-CEO2
03.10.OSE Immunotherapeutics: Appointment of Marc Le Bozec as Interim CEO99Appointment of Marc Le Bozec as Interim CEO Nantes, October 3, 2025, 8:00 a.m. CET - OSE Immunotherapeutics (ISIN: FR0012127173; Mnemonic: OSE) announces the termination of the position as chief...
► Artikel lesen
30.09.OSE Immunotherapeutics: Full renewal of the Board of Directors Election of Dr. Markus Cappel as Chairman of the Board of Directors104Full renewal of the Board of DirectorsElection of Dr. Markus Cappel as Chairman of the Board of Directors Nantes, September 30, 2025, 7:30 p.m. CET - OSE Immunotherapeutics (ISIN: FR0012127173; Mnemonic:...
► Artikel lesen
26.09.OSE Immunotherapeutics - Updated cash position; new collaboration339While OSE Immunotherapeutics' H125 results were previously due to be presented in September, they are now scheduled for 15 October 2025 to allow for the AGM (30 September 2025) to take place ahead of...
► Artikel lesen
26.09.Verzögerung bei AbbVie-Partnerschaft belastet Aktie von Ose Immunotherapeutics15
OSE IMMUNOTHERAPEUTICS Aktie jetzt für 0€ handeln
26.09.Ose Immunotherapeutics shares fall on AbbVie partnership delay5
26.09.OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy3
23.09.OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court131OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court NANTES, France - September 23, 2025, 10:30 p.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) acknowledges...
► Artikel lesen
22.09.Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting4
12.09.OSE Immunotherapeutics: Update on Information Relating to the General Meeting of September 30, 20255
11.09.OSE Immunotherapeutics completes enrollment in lung cancer trial1
11.09.OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell Cancer283OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with...
► Artikel lesen
09.09.OSE Immunotherapeutics Board Urges Support for Value-Driving Strategy and Open-Minded Governance - Publication of Circular for Combined Annual General Meeting of September 30, 202567OSE Immunotherapeutics Board Urges Support for Value-Driving Strategy and Open-Minded Governance Publication of Circular for Combined Annual General Meeting of September 30, 2025 Nantes, September...
► Artikel lesen
08.09.OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders' Annual General Meeting of September 30, 20251
08.09.OSE Immunotherapeutics - executive interview267In this interview, Silvia Comis MD, chief clinical and medical research officer at OSE Immunotherapeutics, covers the company's lead immuno-oncology candidate, Tedopi. She outlines the current unmet...
► Artikel lesen
04.09.OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation166OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation NANTES, France - September 4, 2025, 6 p.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173...
► Artikel lesen
29.08.OSE Immunotherapeutics - Spotlight on OSE's diverse clinical pipeline345OSE Immunotherapeutics has made tangible progress across its clinical development pipeline, creating positive momentum, in our view. In immuno-inflammation, monoclonal antibody therapy lusvertikimab...
► Artikel lesen
Weiter >>
53 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1